Quantcast
Last updated on April 25, 2014 at 1:22 EDT

Latest Antiretroviral drug Stories

2014-04-01 16:25:28

Elizabeth Glaser Pediatric AIDS Foundation Applauds Agreement between the Medicines Patent Pool and ViiV Healthcare WASHINGTON, April 1, 2014 /PRNewswire-USNewswire/ -- The Elizabeth Glaser Pediatric AIDS Foundation (EGPAF) applauds the licensing agreement between the Medicines Patent Pool (MPP) and ViiV Healthcare to increase access to dolutegravir (DTG), a promising new antiretroviral (ARV) medication. This agreement will allow generic manufacturers to scale up production of...

2014-04-01 16:25:15

- Timely collaborations underscore ViiV Healthcare's commitment to increase access to life-saving HIV medicines for children and adults in the developing world LONDON, April 1, 2014 /PRNewswire/ -- ViiV Healthcare today announced new collaborations with the goal of increasing access to its HIV medicine, dolutegravir (marketed under the name Tivicay®), just two months after its approval by the European Medicines Agency (EMA) and eight months after approval by the US Food and Drug...

2014-04-01 08:28:25

RARITAN, N.J., April 1, 2014 /PRNewswire/ -- Janssen Research & Development, LLC (Janssen), today announced it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking approval for a once-daily fixed-dose antiretroviral combination tablet containing darunavir, a protease inhibitor developed by Janssen R&D Ireland and marketed as PREZISTA(®) in the U.S., with cobicistat, an investigational pharmacokinetic enhancer or boosting agent, developed...

2014-03-17 12:27:27

NORWALK, Conn., March 17, 2014 /PRNewswire/ -- UBM Medica US announces that Consultantlive.com, a leading online community for primary care clinicians, offers cutting edge reporting from the Conference on Retroviruses and Opportunistic Infections (CROI 2014). Among the highlights of this premier HIV conference covered on consultantlive.com: -- Making Sense Out of a Plethora of Hepatitis C Clinical Trials Results: It is quite likely that we have entered a new era of treatment...

2014-03-13 17:16:51

New paper in Age and Ageing calls for more routine HIV testing and more collaborative care for older patients with HIV A new paper published online today in the British Geriatrics Society journal Age and Ageing argues that despite a year-on-year increase in the number of people over the age of 50 being diagnosed with the Human Immunodeficiency Virus (HIV), there is a reluctance of healthcare professionals to offer HIV tests to older people. This results in high rates of "late presentation"...

2014-03-06 12:28:29

Company Outlines Future Plans for HIV "Functional Cure" RICHMOND, Calif., March 6, 2014 /PRNewswire/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) today announced the presentation of data from its SB-728-T program to develop a 'functional cure' for HIV/AIDS at the Conference on Retroviruses and Opportunistic Infections (CROI 2014). The conference is being held in Boston from March 3 to 6, 2014. Data from an earlier Phase 1 clinical study in this program were also published in the March 6,...

2014-03-05 16:26:40

Treatment with Sangamo's ZFN- Modified T-cells (SB-728-T) Provides Functional Control of HIV without Antiretroviral Drugs RICHMOND, Calif., March 5, 2014 /PRNewswire/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced today the publication in the New England Journal of Medicine of the first clinical study of its proprietary zinc finger nuclease (ZFN)-based genome editing technology in humans. Data from the study, carried out in HIV-positive subjects, demonstrate that the T-cell...

2014-03-04 13:25:34

A series of papers in the March issue of Health Affairs examines how the Affordable Care Act could affect two sectors of the most vulnerable Americans — those living with HIV/AIDS and people who have recently cycled through jail. The issue features several studies by researchers with the USC Schaeffer Center for Health Policy and Economics, one of the nation's premier policy research centers dedicated to promoting health and value in healthcare delivery through innovative research and...

2014-02-19 11:04:05

Pittsburgh researchers show how therapy-induced resistance to 'NNRTI' drugs works at 58th Annual Biophysical Society Meeting in San Francisco For the more than one million people with HIV/AIDS in the United States (and the over 34 million people living with HIV/AIDS around the world), antiretroviral drugs such as efavirenz and other so-called non-nucleoside reverse transcriptase inhibitors (NNRTIs) in combination with other antiretrovirals can be a lifeline, because they slow the progress...

2014-02-04 11:58:44

Researchers use a naturally occurring HIV variant to trace a T cell lineage for 17 years WHAT: A team of researchers has reported a novel method for tracking CD4+ T cells in people infected with HIV. CD4+ T cells are critical for immune defense against an array of pathogens and are a primary target of HIV. In the study, researchers used a unique, replication-incompetent (defective) form of HIV identified in a patient in the early 1990s. The defective virus had integrated into the genome...


Latest Antiretroviral drug Reference Libraries

0_a4499f7c8759b5cbe79bad5eca319070
2011-01-26 14:08:59

Human immunodeficiency virus (HIV), a lentivirus, causes acquired immunodeficiency syndrome (AIDS) which is a condition in humans were the immune system begins to fail, leading to life-threatening opportunistic infections. Infection is transferred through bodily fluids where HIV is present as both free virus particles and within infected immune cells. The four most common routes of infection are unsafe sex, contaminated needles, breast milk, and transmission from an infected mother to her...

More Articles (1 articles) »